These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 1702565)

  • 1. Endocrine treatment of benign prostatic hypertrophy: current concepts.
    Matzkin H; Braf Z
    Urology; 1991 Jan; 37(1):1-16. PubMed ID: 1702565
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Atamestane: an aromatase inhibitor for the treatment of benign prostatic hyperplasia. A short review.
    el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):565-72. PubMed ID: 7682838
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of a new steroidal aromatase inhibitor, TZA-2237, and/or chlormadinone acetate on hormone-induced and spontaneous canine benign prostatic hyperplasia.
    Ito K; Fukabori Y; Shibata Y; Suzuki K; Mieda M; Gotanda K; Honma S; Yamanaka H
    Eur J Endocrinol; 2000 Oct; 143(4):543-54. PubMed ID: 11022202
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Overview of benign prostatic hypertrophy.
    Geller J
    Urology; 1989 Oct; 34(4 Suppl):57-63; discussion 87-96. PubMed ID: 2477935
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Benign prostatic hyperplasia: pathogenesis and medical therapy.
    Geller J
    J Am Geriatr Soc; 1991 Dec; 39(12):1208-16. PubMed ID: 1720438
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Intratissular androgens in benign prostatic hyperplasia and prostatic cancer.
    Voigt KD; Bartsch W
    J Steroid Biochem; 1986 Nov; 25(5B):749-57. PubMed ID: 2433505
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endocrine therapies for BPH: scientific rationale, clinical results, and patient selection.
    Oesterling JE; el Etreby MF; Gormley GJ; Imperato-McGinley JL; Roehrborn CG; Schröder FH; Tunn UW
    Prog Clin Biol Res; 1994; 386():231-50. PubMed ID: 7528391
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Endocrine therapy for benign prostatic hyperplasia in the 90's.
    Ekman P
    J Urol (Paris); 1995; 101(1):22-5. PubMed ID: 7545721
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The role of sex steroids in the pathogenesis and maintenance of benign prostatic hyperplasia.
    Levine AC; Kirschenbaum A; Gabrilove JL
    Mt Sinai J Med; 1997 Jan; 64(1):20-5. PubMed ID: 8997072
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Aromatase inhibition in the dog. II. Effect on growth, function, and pathology of the prostate.
    Oesterling JE; Juniewicz PE; Walters JR; Strandberg JD; Steele RE; Ewing LL; Coffey DS
    J Urol; 1988 Apr; 139(4):832-9. PubMed ID: 2451040
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Role of estrogens in human benign prostatic hyperplasia.
    Sciarra F; Toscano V
    Arch Androl; 2000; 44(3):213-20. PubMed ID: 10864369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Influence of age and endocrine factors on the volume of benign prostatic hyperplasia.
    Partin AW; Oesterling JE; Epstein JI; Horton R; Walsh PC
    J Urol; 1991 Feb; 145(2):405-9. PubMed ID: 1703242
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of benign prostatic hyperplasia with particular emphasis on aromatase inhibitors.
    Habenicht UF; Tunn UW; Senge T; Schröder FH; Schweikert HU; Bartsch G; el Etreby MF
    J Steroid Biochem Mol Biol; 1993 Mar; 44(4-6):557-63. PubMed ID: 7682837
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Medical therapy for benign prostatic hyperplasia.
    Keetch DW; Andriole GL
    AJR Am J Roentgenol; 1995 Jan; 164(1):11-5; discussion 16-7. PubMed ID: 7527995
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Development of a model for the induction of estrogen-related prostatic hyperplasia in the dog and its response to the aromatase inhibitor 4-hydroxy-4-androstene-3,17-dione: preliminary results.
    Habenicht UF; Schwarz K; Schweikert HU; Neumann F; el Etreby MF
    Prostate; 1986; 8(2):181-94. PubMed ID: 2419882
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Dihydrotestosterone and the concept of 5alpha-reductase inhibition in human benign prostatic hyperplasia.
    Bartsch G; Rittmaster RS; Klocker H
    Eur Urol; 2000 Apr; 37(4):367-80. PubMed ID: 10765065
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Steroid hormones and the pathogenesis of benign prostatic hyperplasia.
    Griffiths K; Eaton CL; Harper ME; Peeling B; Davies P
    Eur Urol; 1991; 20 Suppl 1():68-77. PubMed ID: 1722166
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Pharmacological combinations in the treatment of benign prostatic hypertrophy].
    Di Silverio F; D'Eramo G; Flammia GP; Buscarini M; Frascaro E; Mariani M; Sciarra A
    J Urol (Paris); 1993; 99(6):316-20. PubMed ID: 7516378
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pathogenesis and medical treatment of benign prostatic hyperplasia.
    Geller J
    Prostate Suppl; 1989; 2():95-104. PubMed ID: 2482776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Rationale for using aromatase inhibitors to manage benign prostatic hyperplasia. Experimental studies.
    Habenicht UF; el Etreby MF
    J Androl; 1991; 12(6):395-402. PubMed ID: 1722796
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.